pharmaphorum22h
Multiple studies of Sarepta's DMD therapy halted after death
The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene therapy Elevidys in the wake of the death of a patient who received the ...
Needham & Company LLC Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price reduced by Needham & Company LLC from $202.00 to $183.00 in a report published on Thursday,Benzinga reports. Needham & Company LLC ...
Notable healthcare headlines of the week: Becton, Dickinson, Grifols, Eli Lilly and J&J in focus
Pharma and biotech companies are breathing a sigh of relief after the tariffs announced by President Donald Trump Wednesday afternoon excludes pharmaceuticals.
pharmaphorum22h
Sarepta says early filing for DMD gene therapy is back on
Sarepta is pressing forward with a bold plan to file with the FDA for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD) in the next few months, with a view to ...